10/18/2024

Janusmed sex and gender

Janusmed sex and gender – Eprosartan

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Eprosartan

Eprosartan

Class : A

Show all info

Print

Contact us

  1. Miller JA, Cherney DZ, Duncan JA, Lai V, Burns KD, Kennedy CR et al. Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol. 2006;17(9):2554-60.

  2. Teveten (eprosartan). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-09-16, cited 2021-02-10]

  3. Food and Drug Administration (FDA). Prescribing information - Teveten HCT (eprosartan mesylate/hydrochlorothiazide). Drugs@FDA [www]. [updated 2014-07-22, cited 2021-02-10].

  4. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - TEVETEN HCT (eprosartan mesylate/hydrochlorothiazide). Drugs@FDA [www]. [updated 2001-05-24, cited 2021-02-10].

  5. de la Sierra A, Munoz A, Arcos E, Lopez JS, Relats J, Investigators of the Etapa-II Study. Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension. Blood Press Suppl. 2004;2:5-10.

  6. Hedner T. Management of hypertension: the advent of a new angiotensin II receptor antagonist. J Hypertens Suppl. 1999;17(2):S21-5.

  7. Gradman AH, Gray J, Maggiacomo F, Punzi H, White WB. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension Eprosartan Study Group. Clin Ther. 1999;21(3):442-53.

  8. Punzi, HA and Punzi, CF. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. J Hum Hypertens. 2004;18(9):655-61.

  9. Sachse A, Verboom CN, Jäger B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens. 2002;16(3):169-76.

  10. Food and Drug Administration (FDA). Medical review(s), part 2 - TEVETAN (eprosartan). Drugs@FDA [www]. [updated 2001-06-25, cited 2021-02-10].

  11. Food and Drug Administration (FDA). Medical review(s), part 5 - TEVETAN (eprosartan). Drugs@FDA [www]. [updated 1997-09-09, cited 2021-02-10].

  12. Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29(21):2669-80.

  13. Food and Drug Administration (FDA). Medical review(s), part 6 - TEVETAN (eprosartan). Drugs@FDA [www]. [updated 1997-09-09, cited 2021-02-10].

  14. Yerman T, Gan WQ, Sin DD. The influence of gender on the effects of aspirin in preventing myocardial infarction. BMC Med. 2007;5:29.

  15. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.]

  1. Miller JA, Cherney DZ, Duncan JA, Lai V, Burns KD, Kennedy CR et al. Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol. 2006;17(9):2554-60.
  2. Teveten (eprosartan). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-09-16, cited 2021-02-10]
  3. Food and Drug Administration (FDA). Prescribing information - Teveten HCT (eprosartan mesylate/hydrochlorothiazide). Drugs@FDA [www]. [updated 2014-07-22, cited 2021-02-10].
  4. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - TEVETEN HCT (eprosartan mesylate/hydrochlorothiazide). Drugs@FDA [www]. [updated 2001-05-24, cited 2021-02-10].
  5. de la Sierra A, Munoz A, Arcos E, Lopez JS, Relats J, Investigators of the Etapa-II Study. Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension. Blood Press Suppl. 2004;2:5-10.
  6. Hedner T. Management of hypertension: the advent of a new angiotensin II receptor antagonist. J Hypertens Suppl. 1999;17(2):S21-5.
  7. Gradman AH, Gray J, Maggiacomo F, Punzi H, White WB. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension Eprosartan Study Group. Clin Ther. 1999;21(3):442-53.
  8. Punzi, HA and Punzi, CF. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. J Hum Hypertens. 2004;18(9):655-61.
  9. Sachse A, Verboom CN, Jäger B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens. 2002;16(3):169-76.
  10. Food and Drug Administration (FDA). Medical review(s), part 2 - TEVETAN (eprosartan). Drugs@FDA [www]. [updated 2001-06-25, cited 2021-02-10].
  11. Food and Drug Administration (FDA). Medical review(s), part 5 - TEVETAN (eprosartan). Drugs@FDA [www]. [updated 1997-09-09, cited 2021-02-10].
  12. Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29(21):2669-80.
  13. Food and Drug Administration (FDA). Medical review(s), part 6 - TEVETAN (eprosartan). Drugs@FDA [www]. [updated 1997-09-09, cited 2021-02-10].
  14. Yerman T, Gan WQ, Sin DD. The influence of gender on the effects of aspirin in preventing myocardial infarction. BMC Med. 2007;5:29.
  15. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2020 [cited 2021-03-10.]